| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)NCT03844074 | OTLK | Phase 3 | Completed | 2020-07-23Actual |
| MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)NCT03846219 | Immunic AG | Phase 2 | Active not recruiting | 2020-04-24Actual |
| QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint TherapyNCT03853317 | IBRX | Phase 2 | Terminated | 2021-09-29Actual |
| Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007NCT03853798 | AGIO | Phase 3 | Completed | 2024-07-03Actual |
| Clinical Study Comparing Two Models of a Travoprost Intraocular ImplantNCT03868124 | Glaukos Corporation | Phase 3 | Completed | 2022-06-10Actual |
| Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in JapanNCT03873116 | BioCryst Pharmaceuticals | Phase 3 | Completed | 2021-07-08Actual |
| VELOCITY: An Anthrax Vaccine Clinical StudyNCT03877926 | Emergent BioSolutions | Phase 3 | Completed | 2020-08-06Actual |
| Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian CancerNCT03878849 | Allarity Therapeutics | Phase 2 | Recruiting | 2027-03Estimated |
| The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye DiseaseNCT03879863 | ALDX | Phase 3 | Completed | 2019-10-04Actual |
| Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)NCT03881852 | AXSM | Phase 2 | Completed | 2019-11-27Actual |
| RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical CancerNCT03894215 | AGEN | Phase 2 | Terminated | 2025-03-26Actual |
| Maximizing Outcomes in Treating Acute MigraineNCT03896009 | AXSM | Phase 3 | Completed | 2019-12-10Actual |
| ABX196 in Combination With Nivolumab in Patients With Hepatocellular CarcinomaNCT03897543 | ABVX | Phase 1, Phase 2 | Completed | 2022-04-14Actual |
| A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic CancerNCT03899636 | ANGO | Phase 3 | Active not recruiting | 2025-04Estimated |
| A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and FibrosisNCT03900429 | MDGL | Phase 3 | Active not recruiting | 2028-01Estimated |
| IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell LymphomaNCT03902184 | Innate Pharma | Phase 2 | Completed | 2026-01-08Actual |
| PRO 140 in Treatment-Experienced HIV-1 SubjectsNCT03902522 | CytoDyn, Inc. | Phase 2, Phase 3 | Completed | 2020-05-18Actual |
| A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)NCT03905330 | MIRM | Phase 3 | Completed | 2022-09-01Actual |
| A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye DiseaseNCT03916042 | ALDX | Phase 2 | Completed | 2019-11-22Actual |
| Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia CongenitaNCT03920228 | PVLA | Phase 2, Phase 3 | Completed | 2020-09-19Actual |
| An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular AtrophyNCT03921528 | Scholar Rock, Inc. | Phase 2 | Completed | 2021-01-19Actual |
| Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial SpondyloarthritisNCT03926195 | LKFT | Phase 2 | Completed | 2020-08-14Actual |
| A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal CancerNCT03929666 | Jazz Pharmaceuticals | Phase 2 | Completed | 2025-08-30Actual |
| APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell TransplantNCT03931291 | Aprea Therapeutics | Phase 2 | Completed | 2021-08-27Actual |
| Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell CarcinomaNCT03937219 | Exelixis | Phase 3 | Active not recruiting | 2022-01-31Actual |
| Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)NCT03938246 | SGMT | Phase 2 | Completed | 2021-10-02Actual |
| Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)NCT03940196 | NVCR | Phase 3 | Completed | 2023-05-18Actual |
| Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic CancerNCT03941093 | Kyntra Bio | Phase 3 | Completed | 2024-06-11Actual |
| Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)NCT03945292 | Arrowhead Pharmaceuticals | Phase 2 | Completed | 2021-11-08Actual |
| Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)NCT03946449 | Arrowhead Pharmaceuticals | Phase 2 | Completed | 2022-04-28Actual |
Trial details
- Registry ID
- NCT03844074
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03846219
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03853317
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03853798
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03868124
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03873116
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03877926
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03878849
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03879863
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03881852
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03894215
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03896009
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03897543
- Phase
- Phase 1, Phase 2
Trial details
- Registry ID
- NCT03899636
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03900429
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03902184
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03902522
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT03905330
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03916042
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03920228
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT03921528
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03926195
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03929666
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03931291
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03937219
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03938246
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03940196
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03941093
- Phase
- Phase 3
Trial details
- Registry ID
- NCT03945292
- Phase
- Phase 2
Trial details
- Registry ID
- NCT03946449
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.